Maolactin
Chronic Inflammation
RDC Clinical Pty LtdPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Chronic Inflammation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide University of Colorado, Denver | Phase 4 | BB |
Maltodextrin RDC Clinical Pty Ltd | Phase 3 | BB |
PREDNISONE TABLETS Minneapolis Veterans Affairs Medical Center | Phase 2 | B |
Tirzepatide University of Hawaii | Phase 2 | CCC |
Same molecule, other indications
Maolactin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →